// App-Quantinova.ai

e14019 : Detergent and alcohol free formulation of cabazitaxel: Safety and pharmacokinetics of escalating dose of cabazitaxel lipid suspension (CLS) in patients with advanced solid maliganancies.

Researchers

Presenter

  • Ateeq Ahmad

Principal Investigators

  • Saifuddin Sheikh

  • Mahesh Paithankar

  • Gururaj Deshpande

  • K.C. Lakshmaiah

  • Tanveer M Maksud

  • Ajay Khatri

  • Manjunath K

  • Prashant Kale

  • Ronak Patel

  • Hanmant Barkate

  • Imran Ahmad

Medical Centers

  • Jina Pharmaceuticals, Libertyville, IL

  • Jina Pharmaceuticals, Libertyville, IL

  • Intas Pharmaceuticals Ltd, Ahmedabad, India

  • City Cancer Centre, Vijayawada, India

  • Kidwai Memorial Institute of Oncology, Bangalore, India

  • Unique Hospital - Multispeciality & Research Institute, Surat, India

  • Samvedna Hospital, Varanasi, India

  • Lambda Therapeutic Research, Ltd., Ahmedabad, India

  • Lambda Therapeutic Research, Ltd., Ahmedabad, India

  • Intas Pharmaceuticals Ltd, Ahmedabad, India

  • Jina Pharmaceuticals, Libertyville, IL

Locations

  • United States

  • India

Companies

  • Intas Pharmaceutical

  • Lambda Therapeutic R

  • Jina Pharmaceuticals

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Ribosomal Protein S6 Kinase A3

Drug/Treatment

  • Cabazitaxel

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Open Label

  • Multicenteric

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved